Faecal microbiota transplantation, paving the way to treat non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle change. However, adherence to this approach is often difficult to guarantee. Alteration of the microbiota and an inc...

Descripción completa

Detalles Bibliográficos
Autores: Del Barrio, María, Lavín, Lucía, Santos-Laso, Álvaro, Arias Loste, María Teresa, Odriozola, Aitor, Rodriguez-Duque, Juan Carlos, Rivas, Coral, Iruzubieta, Paula, Crespo García, Javier
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/30084
Acceso en línea:https://hdl.handle.net/10902/30084
Access Level:acceso abierto
Palabra clave:Non-alcoholic fatty liver disease
Gut microbiota
Dysbiosis
Faecal microbiota transplantation
Descripción
Sumario:Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle change. However, adherence to this approach is often difficult to guarantee. Alteration of the microbiota and an increase in intestinal permeability seem to be key in the development and progression of NAFLD. Therefore, the manipulation of microbiota seems to provide a promising therapeutic strategy. One way to do so is through faecal microbiota transplantation (FMT). Here, we summarize the key aspects of FMT, detail its current indications and highlight the most recent advances in NAFLD